A syringe with the needle point to the vaccine vial on the colorful abstract background
MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.
Buffalo, NY - MIMIVAX LLC, a clinical-stage biotechnology company in Buffalo, N.Y., USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM…
Continue Reading MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.